Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are studying a device called the GORE VIABAHN VBX Balloon Expandable Endoprosthesis to treat people with complex iliac occlusive disease, a condition affecting blood flow in the iliac arteries. This clinical trial is designed to compare this device to bare metal stenting, aiming to see which approach better keeps the arteries open over time. The study is prospective, multicenter, randomized, and controlled with a double masking design. Participants will be randomly assigned to one of two groups one receiving the GORE VIABAHN VBX device and the other receiving a commercially available bare metal stent approved for this condition. Treatments focus on the common andor external iliac arteries with lesions between 4 and 11 cm and vessel diameters between 5 mm and 13 mm. Both groups will receive stenting procedures using these devices. During the trial, participants will undergo evaluations to measure artery openness primary patency at one year and up to five years. Additional measures include technical and clinical success of procedures, hemodynamic status, quality of life changes, freedom from restenosis and revascularization, amputation-free survival, and overall survival. The study involves follow-up visits over several years to monitor these outcomes and safety.